Article Type
Review
Published
In this review, the authors summarize the efficacy, safety and mechanism of action of baricitinib for the treatment of alopecia areata and explore the pathophysiological pathways leading to this disorder.
Review
In this review, the authors summarize the efficacy, safety and mechanism of action of baricitinib for the treatment of alopecia areata and explore the pathophysiological pathways leading to this disorder.
Case Series
This article presents a case series including patients with hypertrophic and keloid scars treated with Dermatix, showing that Dermatix is effective for scar treatment and prevention, as well as expert consensus supporting the safe and effective use of Dermatix.
Review
This review aims to familiarize physicians with the clinical features, diagnosis and management of tinea pedis.
Original Research
Recent recommendations by the American Society of Health System Pharmacists and Infectious Disease Society of America have provided guidance regarding vancomycin dosing and monitoring in serious infections; however, trough monitoring for uncomplicated acute bacterial skin and skin structure infections (ABSSSI) were not addressed. Vancomycin use appears to lead to a low incidence of acute kidney injury with short durations and a low trough goal. Nevertheless, clinical studies have found no difference in clinical outcomes for ABSSSI regardless of vancomycin level. Therefore, it can be posed whether trough monitoring is necessary in this patient population. The objective of this study was to determine if vancomycin treatment duration differs for patients with ABSSSI with a sub-therapeutic vancomycin trough (ST; <10 mg/L) compared with therapeutic trough (TT; ≥10 mg/L).
Review
This article aims to review the current knowledge on deucravacitinib, a new oral small molecule that selectively inhibits tyrosine kinase 2 (TYK2), for the treatment of psoriatic arthritis.